nephrolythiasis. Calculus of kidney and ureter
Conditions
Interventions
Intervention 1: In intervention group, patients will receive daily single dose of magnesium oxide with recommended dietary allowance (RDA) in relation to patient's age and sex (30 to 410 mg/kg) and 1-
contain 2 mEq/cc potassium) divided into three doses for three months. Intervention 2: In the control group, patients will receive 1-2 cc/kg potassium Polycitra (220 grams potassium citrate and 66 gra
contain 2 mEq/cc potassium) divided into three doses for three months.
Treatment - Drugs
In intervention group, patients will receive daily single dose of magnesium oxide with recommended dietary allowance (RDA) in relation to patient's age and sex (30 to 410 mg/kg) and 1-2 cc/kg potassiu
In the control group, patients will receive 1-2 cc/kg potassium Polycitra (220 grams potassium citrate and 66 grams citric acid which solute in 1000 cc distilled water
Sponsors
Vice chancellor for research, Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
No minimum to 14 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: All children: 1. Under 15 years of age with sonographic diagnosis of stone. 2. With stones greater than 2 mm diameter; Microlithiasis below 2 mm due to the possible technical errors and less clinical value will be ignored. 3. Who completed informed consent form. Exclusion criteria: 1. Presence of side effects (such as gastritis, gastrointestinal complications due to potassium citrate, sluggishness, lethargy, muscle weakness and diarrhea due to magnesium which drug would be discontinued in this case) 2. Comorbidities which influence tubular secretion such as renal tubular acidosis, pyelonephritis and obstructive uropathy. 3. Not referring in order to sonography and laboratory tests 4. Diagnosed cases who are under medication therapy 5. Over 15 years old age 6. Stones with 2 mm diameter or less 7. Patients need treatment other than conventional therapies such as patients who need hydrochlorothiazide or cystinuria patients who need penicillamine.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| At least 1 millimeter change in stone size during treatment. Timepoint: First day and end of third month. Method of measurement: Sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug side effects such as gastritis and other GI complications due to potassium citrate and muscle weakness due to magnesium. Timepoint: Any time during study. Method of measurement: History and physical examination. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactNayereh Tousi
Mashhad University of Medical Science
Outcome results
None listed